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Introduction 
The globalization of biomedical research has led to the proliferation of clinical and drug 
trials in the developing countries. This is partly because of less stringent regulatory oversight, an 
eager pool of subjects
1
 and lower research cost compared to sponsor countries.
2
  A report issued 
by the Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”) 
in June 2010 confirmed that eighty percent of approved marketing applications for drugs and 
biologics contained data from trials conducted in foreign countries, and more than half of clinical 
trial subjects and sites were located overseas.
3
  The percentage of clinical trials conducted 
outside of the United States and registered by the Food and Drug Administration (“FDA”), has 
increased from five percent in 1997 to twenty-nine percent in 2007, with costs being a major 
driver for the outsourcing.
4
 
 
                                                 
1
 Gina Kolata, Companies Facing Ethical Issues As Drugs Are Tested Overseas, THE NEW YORK TIMES, March 5, 
2004, at A1. 
2
 David M. Carr, Pfizer’s Epidemic: A Need for International Regulation of Human Experimentation in Developing 
Countries, 35 CASE W. RES. J. INT’L L.15, 18 (2003). 
3
 Daniel R. Levinson, Challenges to FDA’s Ability to Monitor and Inspect Foreign Clinical Trials, OFFICE OF 
THE INSPECTOR GENERAL AT THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, June 2010 at 
21, available at http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf  
4
 Steven W. Postal, et al., After Guatemala and Nigeria: The Future of International Clinical Research Regulation, 
24 HEALTH LAW 1, 6 (October 2011). 
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Recently, there has been outcry regarding international research because of unethical 
protocols and in some cases human rights violations in populations that lack understanding of 
research, as certain populations may not consider the activity as research but as a way to receive 
unaffordable medical care.  The concern for harm or injury in research involving vulnerable 
populations like children, pregnant women and fetuses, prisoners, persons with mental and 
behavioral disorders, illiterates, and terminally ill patients have increased because of some of 
these unethical protocols.  Furthermore, industrialized countries benefit more from this research 
than developing countries where the studies are conducted due to financial gains acquired 
through product approval, marketing and high costs.
5
   
Despite the existence of international protections for human subjects of research, some 
study investigators and sponsors have failed to provide subjects in developing countries with the 
same rights accorded research subjects in industrialized countries.  Quite a number of clinical 
studies and trials conducted in developing countries have led to regulatory violations and have 
put vulnerable populations at risk.     
 This paper focuses on biomedical and pharmaceutical research involving unethical 
research in children in developing countries where the accepted international and United States’ 
protections were lacking.  Part I examines the international guidelines for the protection of 
vulnerable populations such as the Nuremberg Code, the Declaration of Helsinki, the 
International Covenant on Civil and Political Rights,  the Council for International Organizations 
of Medical Sciences, and the Belmont Report as well as the United States’ federal frameworks.  
Part II introduces the well-known Pfizer Trovan drug test in Nigeria in 1996 involving unethical 
research protocol, lack of informed consent and assent by the children involved.  Part III 
                                                 
5
 Daniel R. Levinson, supra note 3. 
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critically reviews the process of informed consent of parents and children with diverse socio-
cultural background involved in the research vis-à-vis the international guidelines and United 
States’ regulations for conducting biomedical research involving vulnerable populations.   Part 
IV discusses the current changes to foreign research regulations and offers suggestions for 
improvement of informed consent process in developing countries. 
I.  Protection of Human Subjects in Research 
A. International Protections/Ethical Frameworks 
The international framework for protection of human subjects in research has its bedrock 
in the Nazi doctors’ trial at Nuremberg, Germany.  In 1947, the judges at the Nuremberg 
criminal trials formulated an international standard of human rights for patients involved in 
human experimentation, now known as the Nuremberg Code.
6
 The Nuremberg Code sets the 
international standards for all future ethical and legal questions pertaining to the conduct of 
human experimentation,
7
 and laid down informed consent as the foundation of all ethical 
research with human subjects.  The Nuremberg Code (the “Code”), the Declaration of Helsinki 
(the “Declaration”), the International Covenant on Civil and Political Rights (ICCPR), the World 
Health Organization’s CIOMS Guidelines (“CIOMS GUIDELINES”), and the Belmont Report 
are  five major international guidelines for the protection of human subjects’ right of informed 
consent in experimentation. 
i. The Nuremberg Code 
                                                 
6
 Carr, supra note 2 at 17, (citing Judges Harold Sebring, Walter Beals, & Johnson Crawford, The Nuremberg 
Doctors’ Trial: The Judgment, in HEALTH AND HUMAN RIGHTS: A READER 292-300 (Jonathan M. Mann, et 
al. eds., 1999)). 
7
 Amy F. Wollensack, Closing the Constant Garden: The Regulation and Responsibility of U.S. Pharmaceutical 
Companies Doing Research on Human Subjects in Developing Nations, 6 WASH. U. GLOBAL STUD. L. REV. 747, 
748 (2007) (citing Sharon LaFraniere, Mary Pat Flaherty & Joe Stevens, The Body Hunters, Failure of Consent; The 
Dilemma; Submit or Suffer; ‘Uninformed Consent’ Is Rising Ethic of the Drug Test Boom, WASH. POST, Dec. 19, 
2001 at A1).  
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  The trial of the Nazi doctors and scientists between 1946 and 1947 sets the international 
framework for the protection of human subjects in human experimentation.
8
  During the Second 
World War, the German doctors and scientists led by Dr. Karl Brandt, performed fatal 
experiments on inmates at the concentration camp without their consent.
9
  The human 
experimentation by the Nazi doctors demonstrated a complete disregard of the inherent value of 
human life and a total lack of compassion for the pains and sufferings of the test subjects.
10
    
The unethical human experimentation performed by the Nazi doctors and scientists 
included the following: deliberate infection of subjects with malaria, typhus, yellow fever, 
smallpox, cholera, etc. (to test the efficacy of immunization and drugs); deliberate infliction of 
wounds and then infection with bacteria such as tetanus (to test the efficacy of sulfanilamide and 
other drugs); deliberate poisoning of  subjects’ food for poison experiments; and freezing 
experiments in which subjects were exposed for long hours to temperatures below the freezing 
points or forced to stay inside a tank of ice water.
11
 The trial of the Nazi doctors and the Nazi 
atrocities revelations demonstrated to a shocked world that leaving research subject protection 
and welfare to the sole discretion of an investigator raises the potential for abuses.
12
   
                                                 
8
 Carr, supra note 2 at 20.  
9
 Remigius N. Nwabueze, Ethical Review of Research Involving Human Subjects In Nigeria: Legal and Policy 
Issues, 14 IND. INT’L & COMP. L. REV. 87, 94 (2003-2004). 
10
 Benjamin Mason Meier, International Protection of Persons Undergoing Medical Experimentation: Protecting 
the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 521(2002), (citing Telford Taylor, Opening Statement 
of the Prosecution, December 9, 1946, reprinted in GEORGE J. ANNAS & MICHAEL A. GRODIN, THE NAZI DOCTORS 
AND THE NUREMBERG CODE: HUMAN EXPERIMENTATION 231 (1992)), at 67 (“The defendants in this case are 
charged with murders, tortures, and other atrocities committed in the name of medical science …. To their murders, 
these wretched people were not individuals at all.  They came in wholesale lots and were treated worse than 
animals.”).  
11
 Meier, supra note 10 at 521, (citing UNITED STATES V. KARL BRANDT, 2 TRIALS OF WAR CRIMINALS BEFORE THE 
NUREMBERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW NO. 10 (1948), REPRINTED IN JAYS KATZ, 
EXPERIMENTATION WITH HUMAN BEINGS: THE AUTHORITY TO THE INVESTIGATOR, SUBJECT, PROFESSIONS, AND STATE 
IN THE HUMAN EXPERIMENTATION PROCESS 293 (1972)). 
12
 Kevin M King, A Proposal For The Effective International Regulation of Biomedical Research Involving Human 
Subjects, 34 STAN. J. INT’L L.163, 165 (1998).  See also, Nwabueze, supra note 9, (citing M. GRODIN, Historical 
Origin of Nuremberg Code, in THE NAZI DOCTORS AND NUREMBERG CODE: HUMAN RIGHTS IN HUMAN 
EXPERIMENTATION 121-44 (G.J. ANNAS & M. GRODIN EDS., 1992); Matthew Lippman, The Nazi Doctors Trial and the 
International Prohibition on Medical Involvement in Torture, 15 LOY. L.A. INT’L COMP. L.J. 410 (1993)). 
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In the aftermath of the Second World War, twenty-three Nazi Doctors and scientists were 
accused of war crimes and crimes against humanity and were prosecuted before the Military 
Tribunal at Nuremberg, Germany.
13
 The Nuremberg Code is based on natural law and it protects 
the rights of a subject over the researcher’s right to his or her scientific endeavor.14 The 
Nuremberg Code provides,  inter alia: (1) the voluntary and informed consent of the subjects in 
human experimentation; (2) the experiment must yield fruitful results for the good of society that 
would not have been procurable by any other methods or means; (3) the experiment should be 
conducted as to avoid all unnecessary physical and mental suffering and injury to subjects; (4) 
the degree of risk should be minimal to the subject; (5) the experiment must be conducted only 
by scientifically qualified persons; and (6) in the course of the experiment the subject should be 
at liberty to terminate the experiment where continuation seems impossible to him and  the 
researcher must terminate the experiment if he believes that it may cause harm and injury to the 
subject.
15
 The research subjects cannot voluntarily waive any of the requirements.
16
 The 
principles of the Nuremberg Code set the ethical framework for the United States federal 
regulations and the international guidelines for the conduct of biomedical research.
17
  
Even though the Nuremberg Code has been regarded as the first source of international 
law laying the foundation for all human subject research, it lacked legal force on the individual 
                                                 
13
Meier, supra note 10 at 522-523, (citing  UNITED STATES V. KARL BRANDT, 2 TRIALS OF WAR CRIMINALS BEFORE 
THE NUREMBERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW NO. 10 (1948), REPRINTED IN JAYS KATZ, 
EXPERIMENTATION WITH HUMAN BEINGS: THE AUTHORITY TO THE INVESTIGATOR, SUBJECT, PROFESSIONS, AND STATE 
IN THE HUMAN EXPERIMENTATION PROCESS 296 (1972)). 
14
 Joanne Roman, U.S. Medical Research In The Developing World: Ignoring Nuremberg, 11 CORNELL J.L. & PUB. 
POL’Y 441, 448 (2002). 
15
 The Nuremberg Code, reprinted from Trials of War Criminals before the Nuremberg Military Tribunals under 
Control Council Law No. 10, Vol. 2, pp. 181-182.  Washington, D.C.: U.S. Government Printing Office, 1949, 
available at http://www.hhs.gov/ohrp/archive/nurcode.html (Last visited Dec. 8, 2013). 
16
 Roman, supra note 14 at 449. 
17
 Wollensack, supra note 7 at 749, (citing Michael A. Grodin, Historical Origins of The Nuremberg Code, in THE 
NAZI DOCTORS AND NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 121, 139 (GEORGE J. ANNAS 
& MICHAEL A. GRODIN, EDS., 1992)). 
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states or countries,
18
 and has had little impact on the entire world as its existence has not 
prevented subsequent research scandals.
19
 Physicians and scientists have continued throughout 
the world to use human subjects in medical research without proper consent or adequate 
disclosure of the research to the subjects.
20 
ii. The Declaration of Helsinki 
The Nuremberg Code is criticized due to its lack of legal force and the fact that it relies 
entirely on the researcher to follow the principles set by the code.  These led to the promulgation 
of a set of ethical standards by the medical researchers’ community.  The Declaration of 
Helsinki
21
 (“the Declaration”) was issued in 1964 by the World Medical Association (WMA).  It 
“was the first international regulation written by physicians for physicians,”22 as a direct 
response to the problems perceived in the Nuremberg Code.  The goal of the Declaration was to 
establish a more relaxed medical ethics model that permitted paternalism, expressing a more 
“benign modern attitude toward biomedical research.”23   
The Declaration provides guidance for physicians conducting human subjects’ research;24 
unlike the Nuremberg Code that merely emphasizes voluntary consent as “absolutely 
essential,”25  the Declaration specifically requires that the subject’s “freely given informed 
consent” should be obtained after the subject fully understands the details of the research, 
                                                 
18
 Meier, supra note 10 at 524. 
19
 Id. 
20
 Id., (citing HENRY K. BEECHER, RESEARCH AND THE INDIVIDUAL: HUMAN STUDIES (1970); M.H. PAPPWORTH, 
HUMAN GUINEA PIGS: EXPERIMENTATION ON MAN (1968)). 
21
 The Declaration of Helsinki, WMA 64th General Assembly, Fortaleza, Brazil, October 2013 (the current version), 
available at http://www.wma.net/en/30publications/10policies/b3/ (Last visited Dec. 8, 2013).  
22
 Meier, supra note 10 at 525. 
23
 Roman, supra note 14 at 452. 
24
 1964 Declaration of Helsinki provides that “in any research on human beings, each potential subject must be 
adequately informed of the aims, methods, anticipated benefits and potential hazards of the study and the discomfort 
it may entail.  He or she should be informed that he or she is at liberty to abstain from participation in the study and 
that he or she is free to withdraw his or her consent to participation at any time, ” § I.9. 
25
 Nuremberg Code, Principle I (1947), reprinted in 313 Brit. Med. J. 1448, 1448 (1996). 
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“preferably in writing, formally documented and witnessed.”26 The 1964 Declaration of Helsinki 
has undergone multiple revisions and there have been two notes of clarification added.
27
 The 
sections on informed consent were strengthened with regards to vulnerable subjects, requiring 
the physician to exercise special caution when the subjects cannot give or refuse consent for 
themselves
28
 and those who may be vulnerable to coercion or duress.
29
    
In addition, the Declaration allows consent by proxy from the legal representative of the 
subject in cases of legal or mental incompetence or physical incapacity.
30
  In cases where proxy 
consent cannot be obtained, such as unconscious homeless patients, research should only be done 
if the condition preventing legal competence is a necessary characteristic of the research 
population.
31
  
To protect the consent process, the Declaration provides that research protocol must be 
submitted for review to an independent research ethics committee.
32
 The committee must be 
independent of the researcher, the sponsor and any other undue influence and must take into 
consideration the applicable international norms, laws and regulations of the country wherein the 
                                                 
26
 The Declaration, supra note 21, Principle 26.   
27
 The Declaration, supra note 21.  The Declaration of Helsinki was amended in 1975, 1983, 1989, 1996, 2000, 2008 
and 2013 with notes of clarification added in 2002 and 2004.  
28
 The Declaration recognizes the need for special protection for “vulnerable” individuals participating in research, 
defining “vulnerable” as those who cannot give consent themselves, such as children, supra at note 23, principles 19 
and 20.  In some countries, certain classes of persons are not legally given the right to consent for themselves: such 
as children, women, those suffering from mental disabilities, and other potentially vulnerable groups.  See also 
David M. Carr, supra note 2 at 23, (citing Ruth Macklin, University of the Nuremberg Code, in THE NAZI DOCTORS 
AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 240, 251 (GEORGE J. ANNAS & MICHAEL 
A. GRODIN EDS., 1992)). 
29
 The Declaration, supra note 21, Principle 27. 
30
 Id., Principle 30. 
31
 Id., Principles 28 and 30.  The Declaration provides that “in such circumstances the physician should seek 
informed consent from the legally authorized representative.  If no such representative is available and if the 
research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for 
involving subjects with a condition that renders them unable to give informed consent have been stated in the 
research protocol and the study has been approved by a research ethics committee.  Consent to remain in the 
research should be obtained as soon as possible from the subject or a legally authorized representative.” 
32
 The Declaration, supra note 21, Principle 23. 
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research is to be performed and standards must not reduce or eliminate any of the protections 
prescribed in the Declaration.
33
  
The Declaration of Helsinki, states that “medical research involving human subjects may 
only be conducted if the importance of the objective outweighs the risks and burdens to the 
research subjects … and must be preceded by careful assessment of predictable risks and burdens 
to the individuals and groups involved in the research in comparison with foreseeable benefits to 
them and to other individuals or groups affected by the condition under investigation.”34 
The Declaration of Helsinki, like the Nuremberg Code lacked legal force despite the fact 
that it was the first international regulation written by physicians for physicians.  It is merely a 
guidance document for conducting human subjects’ research. 
iii. The Council for International Organizations of Medical Sciences (CIOMS) 
Guidelines 
  The World Health Organization (WHO) and the Council for International Organizations 
of Medical Sciences
35
 (CIOMS) enacted the International Guidelines for Biomedical Research 
                                                 
33
 The Declaration, supra note 21, Principle 10.  Some other relevant provisions of the Declaration include that: (1) 
only trained and qualified persons should perform research; (2) research should be preceded by assessment of 
predictable risks and benefits; (3) research should only be conducted if its importance outweighs potential burdens 
to subjects; (4) research must be preceded by careful assessment of predictable risks and burdens to the individuals 
and communities involved in the research; (5) participation by competent individuals as subjects in medical research 
must be voluntary.  Although it may be appropriate to consult family members or community leaders, no competent 
individual may be enrolled in a research study unless he or she freely agrees; (6) authors, editors, publishers as well 
as researchers all have ethical obligations with regard to the publication of the results of research;  (7) the refusal of 
a patient to participate in a study or the patient's decision to withdraw from the study must never interfere with the 
medical care rendered; and (8) appropriate compensation and treatment for subjects who are harmed as a result of 
participating in research must be ensured. 
34
 The Declaration, supra note 21, Principles 16 and 17. 
35
 CIOMS is an international, non-governmental organization established by the WHO and United Nations 
Educational, Scientific and Cultural Organization (“UNESCO”) in 1949.   The main objectives of CIOMS are to 
promote international biomedical activities, serve the scientific interests of the international biomedical community, 
and to maintain collaborative relations with the WHO and the United Nations and its specialized agencies.   See 
International Ethical Guidelines for Biomedical Research Involving Human Subjects, available at 
http://www.cioms.ch/publications/layout_guide2002.pdf . 
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Involving Human Subjects (“the CIOMS Guidelines”).36 The CIOMS Guidelines requires that 
each individual give voluntary informed consent and in case of incompetent individuals, the 
permission of the legal representative must be obtained before participating in experimental 
research.
37
   
The CIOMS Guidelines requires that a physician or scientist when obtaining informed 
consent for research, informs the potential patient or subject, of the nature, purpose, methods, 
risks and benefits, the expected duration of the research, alternative treatments available, 
expected benefit to the community, and that the subject is free to refuse to participate or 
withdraw from the research at any time without fear of losing medical care being offered.
38
 
CIOMS Guidelines also expands protections for vulnerable populations
39
 and categorizes 
children as a “vulnerable population” who require special protection.40 With research involving 
children, the CIOMS Guidelines provides that investigator must ensure that: the research might 
not equally well be carried out with adults; the purpose is to obtain knowledge relevant to health 
needs of children; a parent or legal guardian of each child has given consent; assent of each child 
has been obtained to the extent of each child’s capabilities; and a child’s refusal to participate or 
continue in the research is respected.
41
 
                                                 
36
 International Ethical Guidelines for Biomedical Research Involving Human Subjects reprinted in Ethics and 
Research on Human Subjects: International Guidelines 231 (Z. Bankowski & R.J. Levine eds., 1993), available at 
http://www.cioms.ch/publications/layout_guide2002.pdf .  (CIOMS Guidelines). 
37
 CIOMS Guidelines, supra note 36, Guideline 4. 
38
 Carr, supra note 2, at 25-26.  See also CIOMS Guidelines, supra note 36, Guideline 5. 
39
CIOMS Guidelines, supra note 36, Guideline 13, defines “vulnerable populations” as “those who are relatively 
incapable of protecting their own interests,” due to insufficient power, education, intelligence, resources, strength, or 
other needed attributes to protect their own interest.              
40
 Id., Commentary on Guideline 13.  Other vulnerable populations include: (1) persons with mental or behavioral 
disorders; (2) prospective subjects who are junior or subordinate members of a hierarchical group; (3) poor people; 
(4) racial minority groups, and (5) politically powerless persons. 
41
 Id., Guideline 14. 
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The CIOMS Guidelines, like the Declaration of Helsinki, requires Independent Ethical 
Review Committee to review research protocols prior to study commencement.
42
 In addition, the 
CIOMS Guidelines also provides for non-waiver of the right of injured subjects to treatment and 
compensation,
43
 and allows sanctions to be imposed by the hosting state when researchers violate 
local or international standards of ethical conduct in experimental research.
44
 
iv. International Covenant on Civil and Political Rights 
The ICCPR is part of the International Bill of Human Rights, along with the International 
Covenant on Economic, Social and Cultural Rights (ICESCR) and the Universal Declaration of 
Human Rights (UDHR).
45
 In response to Nazi human experimentation during the World War II, 
United Nations incorporated the informed consent doctrine in the context of human 
experimentation in Article 7 of the International Covenant on Civil and Political Rights 
(ICCPR).
46
 The ICCPR is the “only legally binding international treaty concerning human 
experimentation”47 and states or countries ratifying the treaty must comply with its terms,48 and 
as such it has cemented the international status of the Nuremberg Code on the consent 
                                                 
42
 Id. Guideline 2.   See also King, supra note 12, at 183.  Unlike the Declaration of Helsinki (prior to 1989), the 
CIOMS Guidelines requires an independent ethic review committee to approve all experiments involving human 
research subjects. 
43
 CIOMS Guidelines, supra note 36, Guideline 19.  The CIOMS Guidelines distinguishes between those entitled to 
free medical treatment and compensation due to accidental injury during research (non-therapeutic procedures) and 
entitlement of dependants to material compensation for death or disability occurring as a result of direct 
participation in the study. 
44
 Id. 
45
 "Fact Sheet No.2 (Rev.1), The International Bill of Human Rights". United Nations Office of the High 
Commissioner for Human Rights, June 1996. Archived from the original on 13 March 2008. (Last visited Nov. 23, 
2013). 
46
 International Covenant on Civil and Political Rights, December 19, 1966 (entered into force March 23, 1976) 
[hereinafter ICCPR], available at http://www.ohchr.org/en/professionalinterest/pages/ccpr.aspx (Last visited Dec. 
8, 2013). 
47
 Kristen Farrell, Human Experimentation In Developing Countries: Improving International Practices By 
Identifying Vulnerable Populations and Allocating Fair Benefits, 9 J. HEALTH CARE L. & POL’Y 136, 143 (2006), 
(citing Finnuala Kelleher, Note, The Pharmaceutical Industry’s Responsibility for Protecting Human Subjects of 
Clinical Trials in Developing Nations, 38 COLUM. J.L. & SOC. PROBS. 73 (2004)). 
48
 ICCPR, supra note 46, Article 50. 
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requirement.
49
  Article 7 states that “[n]o one shall be subjected to torture or to cruel, inhuman or 
degrading treatment or punishment.  In particular, no one shall be subjected without his free 
consent to medical or scientific experimentation.”50 The United Nations’ principle of informed 
consent, “equates un-consented medical experimentation to torture and cruel, inhuman, and 
degrading treatment.
51
 The prohibition stated in Article 7, guarantees individuals the right to be 
free from any nonconsensual medical experimentation by any entity whether state or private 
actors. 
v. The Belmont Report 
The National Research Act of 1974 created the National Commission for the Protection 
of Human Subjects of Biomedical and Behavioral Research.  One of the charges of National 
Commission “was to identify the basic ethical principles that should underlie the conduct of 
biomedical and behavioral research involving human subjects and to develop guidelines which 
should be followed to assure that such research is conducted in accordance with those 
principles.”52 The Belmont Report was issued on September 30, 1978 and was originally 
published on April 18, 1979 and it established three basic ethical principles: respect for 
persons,
53
 beneficence
54
 and justice.
55
  There are three applications for these ethical principles: 
                                                 
49
 Joanne Roman, supra note 14 at 449. 
50
 ICCPR, supra note 46. 
51
 Wollensack supra note 7, at 751. 
52
 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (1979) [hereinafter The 
Belmont Report], available at http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html (Last visited Dec. 8, 
2013). 
53
 Id.  The principle of respect for persons incorporates at least two ethical convictions; first that individuals should 
be treated as autonomous agents, and second, that persons with diminished autonomy are entitled to protection.  This 
principle requires that a person be given the opportunity to decide what should or should not happen to him. 
54
 Id. The principle of beneficence comprises “two general rules of (1) do not harm and (2) maximize possible 
benefits and minimize possible harms.” 
55
 Id. The principle of justice refers to the ethical obligation to treat each person in accordance with what is morally 
right and proper and also to give each person what is due to him or her.  According to the Belmont Report, “an 
injustice occurs when some benefit to which a person is entitled is denied without good reason or when some burden 
is imposed unduly.” 
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individual voluntary informed consent;
56
 assessment of risks and benefits;
57
 and selection of 
subjects.
58
 
The objective of the Belmont Report is “to provide an analytical framework that will 
guide the resolution of ethical problems arising from research involving human subjects.”59   
However, “unlike most other reports of the Commission, the Belmont Report does not make 
specific recommendations for administrative action  by the Secretary of Health, Education, and 
Welfare.  Rather, the Commission recommended that the Belmont Report be adopted in its 
entirety, as a statement of the Department’s policy.”60 The Belmont Report now serves as a 
historical document and provides the moral framework for understanding regulations in the 
United States on human experimentation.     
Even though the Belmont Report has been instrumental to setting the ethical framework 
on human subjects’ protection in the United States, it has been criticized for failing to provide 
guidance to Institutional Review Boards (IRBs) and researchers in interpreting and applying its 
provisions to individual research studies.
61
 The IRBs and researchers are believed to have 
focused largely on the legal requirements imposed by the Federal regulations while overlooking 
the Belmont Report in reviewing research protocols and conducting research.
62
 
                                                 
56
 Id. The requirement of individual voluntary informed consent derived from respect for persons entails the extent 
and nature of information provided should be such that a reasonable person could adequately decide whether or not 
to participate in the research and such information should be conveyed in a manner and context that the subject 
could understand.   
57
 Id. The requirement of assessment of risk and benefit is derived from the principle of beneficence.  This entails 
the nature and scope of the risks and benefits and the systematic assessment of risks and benefit. It is a method of 
determining whether the risks that will be presented to subjects are justified.   
58
 Id.  The principle of justice finds its application in the requirement that the burdens and benefits of research be 
equitably distributed.  There are two levels relevant to the selection of subjects: social and individual.  It is an 
obligation to treat people with fairness.    
59
 The Belmont Report, supra note 52. 
60
 Id. 
61
 Alice K. Page, Ethical Issues in International Biomedical Research: An Overview, 37 J. HEALTH L. 629, 638, 
(2004). 
62
 Id. 
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The Nuremberg Code, the Declaration of Helsinki, CIOMS Guidelines, the ICCPR and 
the Belmont Report all set the ethical frameworks for protecting the rights of human subjects in 
biomedical research.  As earlier mentioned, the Nuremberg Code sets the ethical framework for 
the United States federal regulations while the Belmont Report sets the moral framework to 
comprehend regulations on human experimentation in the United States.  All these documents 
emphasize the importance of informed consent, the provision of information on risks and 
benefits of the research and the right of subjects to refuse to participate or withdraw at any time 
from the research without fear of any repercussion.  
A. US Regulations on Foreign Research 
The United States has promulgated regulations addressing research involving human 
subjects and the protection for human research subjects is heavily influenced by the Belmont 
Report.  The Federal Regulations, Title 45 of the Code of Federal Regulations, Part 46 
(hereinafter “the Common Rule”) issued by the  Department of Health and Human Services 
(DHHS)
63
 provide ethical guidelines for research involving human research subjects.   When 
research involves pharmaceutical research, the federal government imposes regulation through 
the Food and Drug Administration (FDA) and these regulations are substantially similar to the 
DHHS regulations.   All clinical investigations that support applications for research or 
marketing permits for products regulated by the FDA are subject to the FDA regulations.
64
  
Human subjects’ research involving products regulated by the FDA must comply with both the 
                                                 
63
 The United States Policy for the Protection of Human Subjects published 1991, available at 
http://www.hhs.gov/ohrp/humansubjects/commonrule/  (Last visited Dec. 8, 2013). 
64
 FDA’s Protection of Human Subjects: Title 21 of the Code of Federal Regulations, Part 50 (2013), available at 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.1 (Last visited Dec. 8, 2013). 
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Common Rule if it receives federal funding and FDA regulations governing human subject 
protections.
65
  
i. Federal Regulations – The Common Rule 
The DHHS regulates human subjects’ research in federally funded research66 through its 
Office for Human Research Protection (OHRP).  The OHRP is charged with the basic 
responsibility for developing and implementing the policies, procedures and regulations to 
protect human subjects within the United States.
67
  The OHRP required each institution engaged 
in research to establish IRBs.
68
 The Common Rule requirements for IRB includes: 
membership,
69
 review of research,
70
 criteria for approval of research,
71
 record-keeping,
72
 and the 
documentation of informed consent.
73 
The Common Rule requires that researchers satisfy informed consent requirements, 
including providing an explanation to human subjects; the purposes of the research, the expected 
duration, a description of the procedure, and identification of any procedures which are 
experimental.
74
  Also, research subjects must be informed of any reasonably foreseeable risks or 
discomforts;
75
 provided with a description of any benefits expected from the research;
76
 as well 
as appropriate alternative procedures or treatments.
77
  When research involves more than 
minimal risk, an explanation as to compensation or medical treatment if injury occurs must be 
                                                 
65
 Title 45 C.F.R. § 46.103 (2009). 
66
 Title 45 C.F.R. § 46.101 (2009).   
67
 Press Release, U.S. Department of Health and Human Services, New Office for Human Research Protections 
Created, Dr. Greg Koski Named Director (June 6, 2000), available at 
http://archive.hhs.gov/news/press/2000pres/20000606.html.  
68
 Title 45 C.F.R. § 46.103(b) (2) (2009).   
69
 Title 45 C.F.R. § 46.107 (2009). 
70
 Title 45 C.F.R. § 46.109 (2009). 
71
 Title 45 C.F.R. § 46.111 (2009). 
72
 Title 45 C.F.R. § 46.115 (2009). 
73
 Title 45 C.F.R. § 46.117 (2009). 
74
 Title 45 C.F.R. § 46.116(a) (1) (2009). 
75
 Title 45 C.F.R. § 46.116 (a) (2) (2009).  
76
 Title 45 C.F.R. § 46.116(a) (3) (2009). 
77
 Title 45 C.F.R. § 46.116 (a) (4) (2009). 
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provided to the research subject.
78
  In addition, a statement that participation is voluntary and 
that refusal to participate or withdraw from the study will not result in any repercussion must be 
provided to research subjects.
79
   
The Common Rule provides additional protection for children involved as subjects for 
research
80
 conducted or supported by the DHHS.
81
 The Common Rule provides that the DHHS 
will only conduct or fund research under the following conditions: (1) research that the IRB finds 
to present no greater than minimal risk to children and that adequate provisions are made for 
obtaining the assent of the children and the permission of their parents or guardians;
82
 (2) 
research involving greater than minimal risk but presents the prospect of direct benefit for the 
individual subject;
83
 (3) research involving greater than minimal risk with no prospect of direct 
benefit but likely to yield generalizable knowledge about subject’s disorder or condition;84 and 
(4) research not otherwise approvable but presents an opportunity to understand, prevent or 
alleviate a serious problem affecting the health or welfare of children.
85
  With regards to 
informed consent requirement, the Common Rule requires parents’ or guardians’ permission and 
assent by children.
86
 
The Common Rule, like the international documents setting the ethical frameworks for 
human subjects’ research, stresses the essence of informed consent, the provision of information 
                                                 
78
 Title 45 C.F.R. § 46.116 (a) (6) (2009). 
79
 Title 45 C.F.R. § 46.116 (a) (8) (2009).  See generally Title 45 C.F.R. § 46.116 (2009) General requirements for 
informed consent.  See also Title 21 C.F.R. § 50.20 (2013) for FDA’s similar provisions. 
80
 Title 45 C.F.R. Part 46, Subpart D.  See also Title 21 C.F.R. Part 50, Subpart D on similar FDA protections for 
children in human research. 
81
 Title 45 C.F.R. § 46.401 (2009). 
82
 Title 45 C.F.R. § 46.404 (2009).  See also FDA’s provisions Title 21 C.F.R. § 50.51 (2013). 
83
 Title 45 C.F.R. § 46.405 (2009).  See also FDA’s provisions Title 21 C.F.R. § 50.52 (2013). 
84
 Title 45 C.F.R. § 46.406 (2009).  See also FDA’s provisions Title 21 C.F.R. § 50.53 (2013). 
85
 Title 45 C.F.R. § 46.407 (2009).  See also FDA’s provisions Title 21 C.F.R. § 50.54 (2013). 
86
 Title 45 C.F.R. § 46.408 (2009).  See also FDA’s provisions Title 21 C.F.R. §§ 50.52 (c) and 50.55 (2013). 
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on risks and benefits, and the right to withdraw or refuse to participate in research without fear of 
losing the medical care being provided. 
ii.   The Food and Drug Administration (FDA) Regulations – 21 C.F.R. Part 50 
  Title 21 of the Code of Federal Regulations, Part 50, “Protection of Human Subjects,” is 
the FDA’s regulations governing research involving human subjects.  The FDA requires 
adherence to the informed consent requirements for research aimed at marketing a drug in the 
United States.  Section 50.20, like the Common Rule, provides that: “… no investigator may 
involve a human being as a subject in research … unless the investigator has obtained the legally 
effective informed consent of the subject or the subject’s legally authorized representative.  An 
investigator shall seek such consent only under circumstances that provide the prospective 
subject or the representative sufficient opportunity to consider whether or not to participate and 
that minimize the possibility of coercion or undue influence.  The information that is given to the 
subject or the representative shall be in language understandable to the subject or the 
representative.”87 In the same vein, 21 C.F.R. section 50.27 provides that “informed consent 
shall be documented by the use of a written consent form approved by the IRB, signed and dated 
by the subject or the subject’s legally authorized representative at the time of consent.  A copy 
shall be given to the person signing the form.”88 
 The FDA like the Common Rule emphasizes the significance of informed consent, the 
role of the subject’s legal representative, and most especially minimization of the possibility of 
coercion of subjects participating in research. 
II. Clinical Trials/Studies in Developing Countries involving Children 
                                                 
87
 Title 21 C.F.R. § 50.20 (2013). 
88
 Title 21 C.F.R. § 50.27 (2013). 
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A. Pfizer’s Trovafloxacin Mesylate (Trovan) Test in Nigeria, 1996 (“the Nigerian 
Study”) 
The World Health Organization (WHO) on February 19, 1996 reported the outbreak of 
meningitis in nine States in the northern part of Nigeria, with Kano and Bauchi states having the 
most cases.
89
  The 1996 meningitis epidemic was the worst ever with more than 3,000 deaths and 
several thousand victims suffering from the disease.
90
 Pfizer, an international pharmaceutical 
company, conducted a clinical trial of its new antibiotic, Trovan during this epidemic of 
meningococcal meningitis in children in Kano, Nigeria in April 1996.
91
  At about the same time, 
Pfizer was in the process of conducting clinical trials,
92
  but because animal studies indicated that 
Trovan use may be associated with complications such as bone deformities, joint diseases and 
liver injury,
93
 clinical studies involving human subjects could not be conducted in America.  A 
physician, Scott Hopkins, working with Pfizer learned about the Nigerian meningitis outbreak
94
 
and advised Pfizer of the opportunity to test Trovan in affected children.
95
             
The Nigerian study team was comprised of three of Pfizer’s American physicians and 
four Nigerian doctors with Dr. Abdulhamid Isa Dutse (Dr. Dutse) as the lead investigator.
96
 The 
Nigerian study was conducted at Kano’s Infectious Disease Hospital (“IDH”).97  Pfizer’s new 
antibiotic, Trovafloxacin Mesylate (Trovan), now pending approval from FDA for use on 
children, was administered orally to one hundred sick children while another one hundred sick 
                                                 
89
 World Health Organization, Global Alert and Response (GAR), Cerebrospinal Meningitis in Nigeria, Disease 
Outbreaks Reported (Feb. 19, 1996), available at http://www.who.int/csr/don/1996_02_19c/en/ (Last visited Oct. 
17, 2013). 
90
Carr, supra note 2, at 28. 
91
 Ruth Macklin, Bioethics, Vulnerability, and Protection, Bioethics ISSN 1467-8519 (online), Vol. 17, 475 (2003).  
See also Carr, supra note 2 at 29. 
92
 Wollensack, supra note 7 at 756. 
93
 Wollensack, supra note 7 at 756.  See also Abdullahi v. Pfizer, Inc., 2002 WL 31082956, *1 (S.D.N.Y. 2002) 
(Abdullahi I) 
94
 Wollensack, supra note 7 at 756. 
95
 Id.  
96
 Abdullahi I, supra note 93 at *1. 
97
 Id. 
ADEBOLA A. OLUFOWOBI 
19 
children received a cephalosporin antibiotic (ceftriaxone) at a reduced dose, an FDA-approved 
antibiotic - the standard anti-meningitis treatment but at a reduced dose.
98
  At the end of the two 
week clinical trial, Pfizer’s research team left Kano and never returned for follow-up 
evaluations.
99
  Following the clinical trial, a total of eleven children died: five children who were 
administered Trovan and six who were administered ceftriaxone.
100
  Several children were left 
blind, deaf, paralyzed, or brain-damaged.
101
   
After the conclusion of the Nigerian Trovan Study, Pfizer applied to the FDA for 
approval of the medication for pediatric use in the United States.  Pfizer later withdrew its 
application to use Trovan for epidemic meningitis when the FDA discovered some discrepancies 
in the data while auditing the Nigerian study documents.
102
 Specifically, the FDA informed 
Pfizer of its plan to deny Pfizer’s application to use the Trovan to treat epidemic meningitis and 
also expressed concern about Pfizer’s failure to conduct follow-up examinations.103 However, 
Trovafloxacin was approved for marketing in the United States in December, 1997 for fourteen 
other types of serious infections and it became available on the market in February, 1998.
104
 In 
July 1998, the FDA received over 100 post marketing reports linking Trovan use to serious liver 
injury including four cases that required liver transplantation and the use of the drug was 
suspended.
105
 
                                                 
98
 Abdullahi I, supra note 93 at *2. 
99
 Id. 
100
 Id. 
101
 Id. 
102
 Wollensack, supra note 7, at 757. See also Abdullahi I, supra note 93 at *2. 
103
 Abdullahi I, supra note 93 at *2. 
104
 Murray M. Lumpkin, Food and Drug Administration 09 June 1999 Trovan (Trovafloxacin/Alatrofloxacin 
Mesylate) INTERIM RECOMMENDATIONS,  available at 
http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformatio
nforheathcareprofessionals/publichealthadvisories/ucm053103  
105
 Id.  See also Wollensack, supra note 7 at 757-758. 
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The Nigerian study was tainted with the discovery of falsified ethics committee approval 
letter produced by Dr. Dutse.
106
 The letter was said to have been backdated by Nigerian officials 
working at IDH well after the completion of the study and at a time when there was no ethic 
committee at the IDH
107
 in response to a 1997 FDA audit.
108
     
B. The Pfizer’s Trovan Litigation 
In August 2001, the survivors of the Nigerian Study and their representatives sued Pfizer 
in Abdullahi v. Pfizer, Inc., 2
nd
 Cir. (N.Y.), 2002 WL 31082956 under the Alien Tort Statute 
(ATS) and alleged that the experiment violated law of nations as advised by the Nuremberg 
Code, the Declaration of Helsinki, the International Covenant on Civil and Political Rights (the 
“ICCPR”) and customary international law.109     
The plaintiffs alleged that Pfizer never informed them that they were part of a clinical 
trial, that Pfizer failed to obtain informed consent from the children, their parents or their 
guardians and that the experiment “exposed them to cruel, inhuman and degrading treatment.”110   
The plaintiff also alleged that Pfizer never gave them the option of choosing alternative 
treatment, because they were never informed that Doctors Without Borders was administering 
the effective treatment free of charge in another section of the building.
111
   Pfizer was also 
accused of orally administering Trovan to sick children despite that oral absorption was difficult 
for sick children, failure to conduct testing prior to Trovan administration to determine that 
children in the test had meningitis; and failure to either exclude children with liver or joint 
problems from the experiment or to test for such problems.
112
  Plaintiff also accused Pfizer for 
                                                 
106
 Abdullahi I, supra note 93 at *2. 
107
 Abudullahi I, supra note 93 at *1. 
108
 Abdullahi I, supra note 93 at *2. 
109
Abudullahi I, supra note 93 at *1. 
110
 Wollensack, supra note 7 at 758. 
111
 Abdullahi I, supra note 93 at *2. 
112
 Id. 
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not following its research protocol which called for switching children not responding well to 
Trovan to Ceftriaxone.
113
  Finally, the plaintiffs alleged that Pfizer also failed to conduct regular 
blood tests of children or switch those who suffered from Trovan-related side effects to 
Ceftriaxone.
114
 
In September 2002, the district court dismissed plaintiffs’ claims for forum non 
conveniens.
115
  The district court concluded that Nigeria provided an adequate alternative forum, 
that Pfizer consented to litigation in Nigeria and that Nigeria has a strong interest in the 
litigation.
116
  Representative Tom Lantos of California, the senior Democrat on the House 
International Relations Committee in May 2006, described the findings of a report complied 
about the case by the Nigerian government as “absolutely appalling,” and called for Pfizer to 
open its records.
117
  
The plaintiffs in Abdullahi v. Pfizer appealed the district court’s dismissal of their suit on 
the basis of forum non conveniens to the United States Court of Appeals for the Second 
Circuit.
118
 In January 2009, the Court of Appeals for the Second Circuit ruled that the Nigerian 
victims and their families were entitled to bring suit against Pfizer in the United States under the 
Alien Tort Statute, stating that the “prohibition on nonconsensual medical experimentation on 
human beings constituted a universally accepted norm of customary international law, and 
consequently an alleged violation” that fell within the jurisdiction of Alien Tort Statute.119    
Following the Second Circuit’s reversal of the district court’s decision, in February 2011, 
Pfizer settled all remaining cases filed in Nigeria by the Nigerian government and in New York 
                                                 
113
 Id. 
114
Id.  
115
 Abdullahi I, supra note 93 at *12. 
116
 Id.  See also Wollensack, supra note 7 at 759. 
117
 Joe Stephens, Panel Faults Pfizer in ’96 Clinical Trial in Nigeria, THE WASHINGTON POST, May 7, (2006), 
available at http://www.washingtonpost.com/wp-dyn/content/article/2006/05/06/AR2006050601338.html.  
118
 Abdullahi v. Pfizer, Inc., 562 F.3d 163 (2nd. Cir. 2009). 
119
 Id. 
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by parents and guardians
120
 for $75 million; the settlement was subject to a confidentiality 
clause.
121 
Another example of human subject research involving children in developing countries 
was the proposed “Testing a New Surfactant in Bolivia.”122  In 2000, Discovery Laboratories of 
Doylestown, Pennsylvania, proposed a phase 3 study to test the efficacy of a new drug called 
Surfaxin for treating idiopathic respiratory distress syndrome (“RDS”) in premature newborn 
infants in a placebo controlled study in Bolivia and three other Latin American countries.
123
  The 
study population would consists of 650 premature infants with RDS in a double-blinded, 
randomized, two–arm placebo-controlled trial,124 with a control group of 325 premature infants 
to be treated with placebo.
125
  
 Surfactant was unavailable for treatment of RDS at the proposed hospitals for the study 
and the sponsor proposed to provide training, support, the necessary equipment and antibiotics 
for all study subjects.
126
  For the proposed study, the “parents of the infants with RDS symptoms 
would be asked to give consent for their infants to participate in the study.”127 Once consent has 
been obtained, the infants would be intubated with an endotracheal tube by a health care 
                                                 
120
 Steven W. Postal, et al., A Remedy in Sight: International Clinical Research Regulation in the Wake of 
Guatemala and Nigeria, 6 PITT. J. ENVTL PUB. HEALTH L. 1, 21 (2011). 
121
 Id.  The Nigerian Kano State government filed both civil and criminal charges against Pfizer in 2007.  The 
Nigerian federal government also sued Pfizer and individual employees for billions of dollars in damages.  See also 
Joe Stephens, Pfizer to Pay $75 Million to Settle Trovan-Testing Suit, THE WASHINGTON POST, July 31, (2009), 
available at http://articles.washingtonpost.com/2009-07-31/news/36811829_1_trovan-pfizer-chief-executive-
william-c-steere. There have been a lot of scholarly written articles on the Abdullahi Litigation, for more detailed 
account and analysis, see Amy F. Wollensack,  Closing the Constant Garden: The Regulation and Responsibility of 
U.S. Pharmaceutical Companies Doing Research on Human Subjects in Developing Nations, 6 WASH. U. GLOBAL 
STUD. L. REV. 747 (2007). 
122
 The Proposed Bolivia Study. 
123
 Fred Charatan, Surfactant trial in Latin American Infants criticized, BMJ 322:575.3, 2001, (Mar. 10, 2001), 
available at http://www.bmj.com/content/322/7286/575.3?tab=related.  
124
 JAMES V. LAVERY, CHRISTINE GRADY, ELIZABETH R. WAHL, EZEKIEL J. EMANUEL, ETHICAL 
ISSUES IN INTERNATIONAL BIOMEDICAL RESEARCH, (A Casebook, eds., 153, Oxford University Press, 2007).  
125
Charatan, supra note 122.  
126
 Lavery, et al., supra note 123.  
127
 Id. 
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provider, who would then administer either air suffused with Surfaxin or air without any drug.
128
  
The endpoints for the proposed study were number of deaths from any cause by day 28 and 
deaths due to direct or indirect complications of RDS.
129
  There were no specific plans to market 
Surfactant in Latin America, while the United States and Europe were the principal target market 
for the drug.
130
  The sponsor proposed to make Surfaxin available at a very low cost in the 
countries of the proposed study, if proved effective.  However, there was no firm agreement 
reached on the negotiation.
131
 According to Dr. Sidney Wolfe
132
the infants in the placebo arm are 
being used by Discovery Laboratories “for reasons having to do with corporate bottom lines in 
order to get their drug approved.”133 
 Despite the Nigerian Trovan Study experience, researchers continue to throw caution to 
the winds by involving human subjects in research that is greater than minimal risk.  If the 
Proposed Bolivia Study had not been halted, it would have been another exploitation of 
vulnerable populations that may have resulted in unnecessary deaths. 
 
III. Analysis of Ethical Issues Arising from the Nigerian Trovan Study 
A. Informed Consent and Socio-Cultural Factors 
Informed consent is the basis of the relationship between patients and physicians and in 
the case of clinical research, between the subjects and the researcher.
134
  Both the international 
guidelines
135
 and the United States regulations on human subject research
136
 all require the 
voluntary informed consent of the subjects.  The Nuremberg Code requires absolute voluntary 
                                                 
128
 Id.   
129
 Id. 
130
 Id.  
131
 Id. at 154. 
132
 The Director of Public Citizen’s health research group. 
133
 Charatan, supra note 122. 
134
 The investigators and sponsors of the research also owe a duty to obtain voluntary informed consent from the 
subjects. 
135
 The Nuremberg Code, the Declaration of Helsinki, the ICCPR, the CIOMS Guidelines, and the Belmont Report. 
136
 The Common Rule, Title 45 C.F.R. Part 46 and the FDA regulation, Title 21 C.F.R. Part 50. 
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consent from subjects.
137
  It approaches voluntary consent through a moral approach because the 
society regards people are self-autonomous, while the Declaration of Helsinki and the CIOMS 
Guidelines approach voluntary consent from the doctor-patient and the patient and surrounding 
circumstances respectively.
138
   
The Nuremberg Code does not address socio-cultural factors affecting the doctrine of 
informed consent.  The Declaration on the other hand, did not specifically addressed socio-
cultural factors but it allows physicians to follow research subjects’ national laws and 
standards.
139
 The CIOMS Guidelines recognizes socio-cultural factors on informed consent but 
provides that permission of a community leader or other authority may not be substituted for 
individual informed consent.
140
  In many developing countries, like Nigeria for example, it is 
customary in some communities for community leaders to give consent on behalf of its 
members.  In some patriarchal cultures, females are prohibited from making personal important 
decisions for themselves or on behalf of their children.
141
  Nigeria as a country is a multi-
cultural, multi-ethnic, and multi-religious nation
142
  and the perceptions on health issues are 
strongly influenced by these factors as well as the belief in the extended family system.
143
 
Northern Nigeria has a strong centrally-controlled feudal system that has strong influence on the 
decision to undertake treatment, which sometimes could be detrimental to the patient.   
                                                 
137
 The Nuremberg Code, supra note 15, at art.1. 
138
 Carr, supra note 2, at 31.  
139
 The Declaration, supra note 21, Principle 10. 
140
 The CIOMS Guidelines, supra note 36, Commentary on Guideline 4. 
141
Carr, supra note 2, at 32. 
142
 Lawal Y Z, Garba E S, Ogirima M O, Dahiru I L, Maitama M I, Abubakar K. The Doctrine of Informed Consent 
in Surgical Practice. Ann Afr Med [series online] 2011 [cited 2013 Aug. 28]; 10:1-5, available at 
http://www.annalsafrmed.org/text.asp?2011/10/1/1/76558.  
143
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In such culture, “community consent clashes with the Declaration’s policy that 
individuals personally volunteer for the experimental procedure.”144 As David Carr noted, if a 
country does not codify the community consent concept within its laws, researchers would be 
left with no guidance to deal with communities that traditionally allow community consent.
145
In 
Pfizer’s Trovan case however, conducting an experimental research along with providing 
charitable medical care to sick people may lead to misconception by the patients who may not 
necessarily volunteer for the research but for the treatment.
146
 Under such circumstance, where 
medical treatment is being rendered by charitable organizations, it is easy for a subject to mistake 
the experimental research for treatment and thereby “disposing of the need for researchers to 
obtain consent.”147 
B. Lack of Informed Consent and Potential for Exploitation of Vulnerable Research 
Subjects 
The heart of the issue in the Nigerian Trovan Study was that Pfizer allegedly did not 
obtain informed consent of the subjects in accordance with international guidelines and the FDA 
regulations.
148
  The Nigerian Trovan Study involved pharmaceutical research and thus the FDA 
has jurisdiction over the Trovan clinical study.
149
 The Nigerian Trovan Study arguably violated 
Title 21 C.F.R. § 50.20 which requires that researchers or investigators obtain informed consent 
from the subject or the subject’s legally authorized representative, provide information in 
language understandable to the subject or the representative, provide subject or the representative 
enough opportunity to consider whether or not to participate in the research, as well as minimize 
                                                 
144
 Carr, supra note 2 at 34. 
145
 Carr, supra note 2 at 33. 
146
 Carr, supra note 2 at 34. 
147
 Id.  
148
 Abdullahi v. Pfizer, Inc., supra note 117 at 169.  See also 21 C.F.R. § § 50.20 and 50.55 (2013), CIOMS 
Guidelines; The Declaration of Helsinki and The Nuremberg Code. 
149
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the possibility of coercion or undue influence.
150
 The subjects claimed that neither they nor their 
parents were told that they were part of a clinical trial.
151
 Also, a Nigerian laboratory technician 
was reported to have corroborated this fact, saying they “did not know if it was research or not,” 
“they just knew they were sick.”152 This arguably was a contravention of Article 7 of ICCPR 
with regards to informed consent of human subject research which prohibits nonconsensual 
medical or scientific human experimentation.
153
   Local nurses were said to have explained the 
research to the families in their native language,
154
 but did not provide full translation of the 
consent form.
155
  Thus, there were significant flaws with adequacy of the informed consent 
sought and obtained from subjects. 
The Declaration of Helsinki,
156
 the CIOMS Guidelines
157
 and the FDA regulations
158
 all 
require documentation of informed consent.  21 C.F.R. section 50.27 states “informed consent 
shall be documented by the use of a written consent form approved by the IRB and signed and 
dated by the subject or the subject’s legally authorized representative at the time of consent. A 
copy shall be given to the person signing the form.”159 In this case, Pfizer could not produce any 
consent form documenting the informed consent procedure as required by both international 
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 Title 21 C.F.R. § 50.20 (2013). 
151
 Abdullahi I, supra note 93 at *1. 
152
 Joe Stephens, Where Profits and Lives Hang in Balance, Washington Post, Dec. 17, 2000, available at 
http://www.washingtonpost.com/wp-dyn/content/article/2007/07/02/AR2007070201255.html. 
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 ICCPR supra note 46.   
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 Id.  
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 Stephens, supra note 151.  It should be noted that Kano where the study was conducted is one of the northern 
states in Nigeria, whose residents are mainly Hausas and Fulanis who are mostly illiterates and could not have been 
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 CIOMS Guidelines, supra note 36, Guideline 4 Commentary. 
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guidelines and FDA regulations.
160
 Even though Pfizer asserted to have obtained verbal consent 
and that local nurses spoke with the families, the company admitted that no witnesses attested to 
the verbal consent given.
161
 
This situation and other factors
162
 surrounding it, is a clear case of exploitation of 
vulnerable population; the subjects involved were poor sick children whose parents or guardians 
are illiterates
 
who were looking for treatment to alleviate their health conditions.  The CIOMS 
Guidelines categorizes children, the poor and illiterates as a vulnerable population and requires 
special justification when these groups are invited to serve as research subjects, “and if they are 
selected, the means of protection of their rights and welfare must be strictly applied.”163 The 
Nigerian Trovan Study clearly contravenes the CIOMS Guidelines on this issue, because Pfizer 
failed to obtain consent from the subjects’ parents or guardians and to protect their welfare.164 
The Declaration also requires caution when research involves vulnerable populations and that 
research is only justified if it is responsive to the health needs of the group.
165
Arguably, Pfizer 
exploited the subjects’ situation of need (outbreak of meningitis and need for treatment) and 
experimented on them, when they were merely looking to cure their disease.
166
Pfizer 
administered Trovan orally to the sick children solely to get FDA’s approval of its application167 
and also failed to protect the welfare of the sick children who did not respond well to Trovan as 
they were not switched to Ceftriaxone.
168
  Moreover, the subjects’ parents are illiterates who 
could not speak or understand English language; they simply believed their children were 
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receiving effective treatment for meningitis rather than being enrolled in an experimental 
research.
169
   
If the “proposed Bolivia Study” had been allowed to see the light of the day, it would 
have been another case of wrongful exploitation of vulnerable population.   It would have been a 
case of medical experimentation for profit carried out in poor countries and on sick children.  
The “proposed Bolivia Study” could have met the requirement for informed consent but would 
have been a case of exploitation as there was no plan to make the drug available in the host 
country because it would have been expensive and unaffordable.
170
  
The main purpose of the Trovan study performed by Pfizer was to gain approval for 
marketing of the drug in the United States can be construed as a premeditated case of 
exploitation of vulnerable population as they were not meant to benefit from the research.
171
 In 
the Bolivian case, the intention to use placebo when there were four approved surfactants in use 
in the United States contravenes the Declaration of Helsinki, which states “The benefits, risks, 
burdens and effectiveness of a new intervention must be tested against those of the best proven 
intervention(s)…”172 This research would have caused unnecessary deaths in the placebo arm. 
C. Lack of Risk and Benefit Information 
Subjects in the Nigerian Trovan Study claimed Pfizer never informed them of the 
potential risks involved – a situation which would have been deemed unethical in the US, leaving 
eleven children dead and several others disabled.
173
  The FDA’s regulations regarding involving 
children in minimal risk research
174
 was not adhered to by Pfizer.  The study deviated from the 
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standard of care for meningitis by administering Trovan orally to the Nigerian children, whereas 
in the United States and other developed countries, the standard of care is intravenous 
antibiotics.
175
  Furthermore, Pfizer administered Trovan to the Nigerian children despite animal 
studies indicating that Trovan use may be associated with bone deformities, joint diseases and 
liver injury.
176
 
Arguably, Pfizer violated the principle of The Declaration of Helsinki on risks, burdens 
and benefits assessment which states that “medical research involving human subjects may only 
be conducted if the importance of the objective outweighs the risks and burdens to the research 
subjects … and must be preceded by careful assessment of predictable risks and burdens to the 
individuals and groups involved in the research in comparison with foreseeable benefits to them 
and to other individuals or groups affected by the condition under investigation.”177  Since prior 
animal studies linked Trovan’s use to increases morbidity and perhaps mortality from liver 
injury, joint diseases and bone diseases, the burdens of the Nigerian Trovan Study is foreseeable 
and clearly outweigh the benefits.  Therefore, Pfizer should not have used this medication or at 
least communicated these risks explicitly to the subjects’ parents or guardians. 
D. Lack of Independent Ethical Review 
The Declaration of Helsinki, the CIOMS Guidelines and the FDA’s regulations require 
that an ethics review committee review and approve research protocols prior to conducting a 
medical research involving human subject.
178
  The case is different in Nigeria and many other 
African countries where there is neither state nor federal formal regulatory system of ethics 
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review or research guidelines issued by the country’s medical research institutions.179  Nwabueze 
noted that the “regulatory deficiency was probably responsible for the Trovan tragedy in 
Nigeria.”180 It has been reported that in a survey conducted by the National Bioethics Advisory 
Committee, one-fourth of all clinical trials conducted in foreign countries went through no 
ethical review at all.
181
 
Pfizer asserted that the Nigerian Trovan Study was approved by a Nigerian ethics 
board;
182
 but investigation revealed that at the time of the study, there was no ethics review board 
at the hospital where the study was conducted.
183
 In response to a 1997 FDA’s audit 
investigation, Dr. Dutse, Nigerian lead investigator “in charge of local aspects of the study 
admitted that his office falsified document stating approval of the study by an ethics review 
board”.184 According to an FDA official, “a knowing submission of false documents to a US 
government agency is a violation of federal law.”185 Even though the FDA has jurisdiction over 
“clinical research and protection of child subjects, there are no provisions explicitly protecting 
against fraud.”186 
While research is encouraged for advancement of health and prevention of diseases, 
market forces and lack of concern for distributive justice (access to the intervention if beneficial) 
sometimes can lead to exploitation especially in developing countries with little or no basic 
healthcare, large number of naïve, poor, and illiterate human subjects.   More stringent 
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safeguards and protections could be put in place, specifically to address each of the factors that 
could lead to exploitation. 
IV. Current Changes to Foreign Research Regulations and Suggestions for Improvement. 
A.  Impact of Pfizer’s Trovan Study in Nigeria on Foreign Research Regulations 
In the aftermath of the Nigerian Trovan Study, there have been a lot of commentaries and 
articles written condemning the unethical conduct and abuses involved.  In response, there have 
been amendments to both international guidelines and the United States’ regulations on human 
subject research in developing countries.  
i. The Declaration of Helsinki 
The Declaration of Helsinki has been revised multiple times and there have been two 
notes of clarification added.
187
 The 2013 Declaration
188
 includes several subsections which 
enhance and provide clarity on some specific issues; thus making the 2013 Declaration “a better 
and more important authority … providing guidance on conducting medical research involving 
humans.”189 The 2013 Declaration of Helsinki addresses some of the ethical issues in biomedical 
research in developing countries.  It identifies and encourages researchers to pay attention to 
socio-cultural factors that may affect obtaining voluntary informed consent.
190
  For example, in 
some cultures, community leaders or heads of household serve as additional layer of protection 
that researchers must pass through before obtaining informed consent from potential subjects.
191
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It also encourages compensation and treatment of subjects when injury occurs during a study,
192
 
as well as subjects’ access to proven interventions or drugs after the study.193 It discourages the 
use of placebo unless where proven interventions are non-existent.
194
  Finally it emphasizes the 
importance of ethics committee’s review of study protocols, monitoring ongoing studies for 
adverse events and the need to terminate a study if safety concern arises.
195
  
 With the Declaration of Helsinki 2013 specifically addressing research issues pertaining 
to research in developing countries, its influence in serving as an important international 
document to stakeholders in limited-resource settings should increase.
196
  And for research 
sponsors, ethics committees, and subjects, the current version of the Declaration of Helsinki 
should be empowering given its emphasis on issues of justice.
197
 
ii. The Food and Drug Administration (FDA) Policies on Foreign Research 
The FDA has likewise modified its regulations on human subject research in foreign 
countries following the devastation caused by the Nigerian Trovan Study.  The FDA on April 28, 
2008 promulgated regulations on the acceptance of foreign clinical studies not conducted under 
an investigational new drug application (“The 2008 Rule”).198 The 2008 Rule has been said to be 
part of the FDA’s effort to issue more binding regulations rather than industry guidance 
regarding clinical trials.
199
 The 2008 Rule was promulgated to help ensure the protection of human 
subjects enrolled in non-IND foreign clinical studies as well as the quality and integrity of the 
resulting data.  The 2008 Rule requires that foreign clinical studies for marketing applications 
must be conducted in accordance with good clinical practice (GCP); include a review and 
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approval by an independent ethics committee (IEC) and written informed consent from 
subjects.
200
  
a. Informed Consent of Subjects 
The 2008 Rule added additional layer of protections to human subjects’ research on the 
issue of informed consent.  It makes it mandatory for sponsor or applicant to disclose to the FDA 
a description of how and when informed consent was obtained from the subjects,
201
 such as a 
written document that is witnessed, signed and dated from the research subject.  However, 
informed consent of the subject is not required in certain life-threatening circumstances
202
 such 
as when a lifesaving compassionate medical treatment or intervention is urgently needed and the 
clinician is unable to communicate with either the subject because of coma or his/her legal 
representative because of unavailability, or when there is no alternative method of therapy that 
provides equal or greater likelihood of saving the subject’s life.203 In such situations, it is the 
responsibility of the IEC to conduct its review before the study begins, make a finding that 
obtaining informed consent is not feasible, and either find that the conditions present are 
consistent with those described in section 50.23 or section 50.24(a) of 21 C.F.R., or that the 
measures described in the study protocol or elsewhere will protect the rights, safety, and well-
being of subjects.
204
 
b. Review and Approval by Independent Ethics Committee (IEC) 
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The 2008 Rule defined an Independent Ethics Committee as “a review panel that is 
responsible for ensuring the protection of the rights, safety, and well-being of human subjects 
involved in a clinical investigation and is adequately constituted to provide assurance of that 
protection.”205  It makes it mandatory that foreign clinical trials be reviewed and approved by an 
Independent Ethics Committee,
206
 and clarifies that an IRB is a type of IEC.
207
 
The 2008 Rule requires the sponsor or applicant to submit information, including the 
name and address of the IEC that reviewed the study; a statement of the IEC’s qualification in 
accordance to section 312.3; maintenance of supporting records containing the names and 
qualifications of the IEC members must be kept and be available for the agency’s review; 
submission of the names and qualifications of the IEC members that reviewed the study and a 
summary of the IEC’s decision to modify or approve the study or a favorable opinion of the 
study.
208
 
c. Good Clinical Practice 
The 2008 Rule defines Good Clinical Practice “as a standard for the design, conduct, 
performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in a way 
that provides assurance that the data and reported results are credible and accurate and that the 
rights, safety, and well-being of trial subjects are protected.”209  The 2008 Rule also requires that 
GCP include oversight by an IEC and obtain informed consent of subjects.
210
  The 2008 Rule 
clarifies the limited circumstances in which GCP would not require informed consent.
211
 In such 
life-threatening situations, the IEC has a responsibility to review the study, make a finding that 
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obtaining informed consent was not feasible, and that the conditions present are consistent with 
those described in section 50.23 or 50.24(a) of Title 21 C.F.R.
212
 The purpose of the GCP 
requirement for non-IND foreign clinical studies is to help ensure proper conduct of trials, 
protect data quality and integrity.
213
  
The United States Department of Health and Human Services (DHHS) in its bid to offer 
more protection for human subject research is in the process of amending the current 2008 Rule.   
The proposed changes under consideration can be found in an Advance Notice of Proposed 
Rulemaking (“ANPRM”),214 and are designed to strengthen protections for human research 
subjects.  These proposed changes include but not limited to: creation of a single website for the 
electronic reporting of all events and to harmonize the reporting requirements across agencies; 
provision of specificity on how consent forms should be written to contain all necessary 
information that would facilitate participant’s quality decision to participate or not in a study.  
Also the ANPRM proposes to extend federal regulations protection to all studies involving 
human subjects conducted in the U.S. regardless of funding source.
215
 
Even though the ANPRM does not include studies or trial conducted in foreign countries, 
it could be argued that since most of these studies fall under the supervision of the FDA, the 
changes regarding having a single database for reporting all events and revision to the consent 
form would apply to foreign research involving human subjects.  With a single database for 
reporting all clinical trial events, it would foster transparency and minimizes exploitation of 
research subjects.  Most especially, a shorter consent form that is more readily understood and 
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less confusing would enhance the quality of decisions of research subjects in developing 
countries. 
B. Suggestions for Improvement of Informed Consent Process in Developing Countries 
The informed consent doctrine continues to be an integral part of research whether 
conducted locally or internationally.  Binding regulations ratified and enforced by all nations 
involved in human subject research in developing countries are urgently needed to protect the 
right, dignity and safety of subjects.  The elements of informed consent and independent ethics 
review board needs to be strengthened and enforced globally with high standard for international 
research in developing countries.   Most times, the host country do not benefit from a new drug 
or intervention due to poverty and inadequate health care funding by host government.  
Therefore, regulations should promote equitable distribution of burdens and benefits for research 
conducted in developing countries by making proven intervention available to research subjects 
and the host countries. 
 Human subjects’ research continues to be an important aspect of medical advancement; 
however, private companies see this as more of economic benefit than medical and knowledge 
venture.  Children are precious, innocent and very vulnerable and should not be subjected to 
inhumane and degrading treatment all in the name of advancing medical knowledge, treatment or 
cure for diseases.  Children deserve self-respect like every other person, and should not be 
exploited simply by origin of their birth or because they are unable to make decisions as to what 
should be done to their bodies.  Even when parents volunteer their children for medical 
experimentation, it should not be seen as a means of exploitation, they are individuals and should 
never be treated as “objects” or “tools” for achieving scientific or medical knowledge.  Echoing 
the words of Francis Payton Rous, editor of the Journal of Experimental Medicine, in 1941 he 
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stated in a letter rejecting a manuscript from a physician that “the inoculation of a twelve month 
old infant with herpes … was an abuse of power, an infringement of the rights of an individual, 
and not excusable because the illness which followed had implications for science.”216  The fact 
that “a child was ‘offered as a volunteer’ – whatever that may mean – does not palliate the 
action.”217 
Considering the controversy and several litigations surrounding the Pfizer Trovan 
Nigerian Study on informed consent, this paper offers the following suggestions for improving 
informed consent process in developing countries, particularly for research involving children as 
subjects.   The informed consent form must be approved by the host country’s independent ethics 
review committee and the federal health agency charged with regulating and controlling the 
manufacture, importation, distribution, sale and use of drugs and medical devices.   Informed 
consent must be voluntary and the consent form must be written in simple easily comprehensive 
words (native language where applicable).  There should be a proper and accurate documentation 
of the informed consent process; a copy of the signed consent form must be kept in the research 
file and must also be given to the research subject or legal representative.   In cases where it is 
not possible to provide a full and accurate translation of the consent form in the applicable native 
language, services of certified local medical interpreter should be employed and proper 
documentation must be kept in the research file.  Furthermore, investigators and researchers 
should be specifically required to provide adequate clarification between experimental research 
and charitable aid.
218
 
Conclusion  
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International biomedical research in developing countries continues to be faced by ethical 
challenges because of a multitude of factors such as sociocultural differences, literacy rate, 
wealth, access to basic health care, politics and market forces driving big pharmaceutical 
companies in developed countries.  The risk benefit ratio of potential harm to subjects must be 
strongly considered to the knowledge gained from such research.  Sometimes these risks- 
benefits assessment are not done especially when researches are driven by market force from 
private and multinational pharmaceutical companies that eventually lead to injustice and 
exploitation of vulnerable populations; this is the case in the Nigerian and the proposed Bolivian 
studies.   
 
 
 
 
 
 
 
 
 
 
  
